Bavarian Nordic A/S
Research Bavarian Nordic A/S (0DPB) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- Ticker0DPB
- ExchangeLSE
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyDKK
- Financial periodFY2025
- RevenueDKK 6.24B
- Net incomeDKK 1.38B
- Free cash flowDKK 1.36B
- Gross margin48.8%
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 6.24B | DKK 1.38B | DKK 1.36B | 48.8% | n/a | DKK 1.71B | DKK 130.87M | DKK 12.87B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-10 | n/a | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 DKK.
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Bavarian Nordic A/S do?
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses.